uGDB, utilizing next-generation sequencing to detect bladder cancer-associated mutations and DNA alterations, has previously shown associations with recurrence and therapy response.

Enfortumab vedotin plus pembrolizumab followed by surgery showed high complete response rates in advanced urothelial cancer.

Douglas A. Tremblay, MD, discusses the data showing disease-modifying potential of ropeginterferon alfa-2b-njft in patients ...